Literature DB >> 25854121

[Motility disorders of the small intestine].

J Keller1, P Layer.   

Abstract

Chronic intestinal pseudo-obstruction (CIPO) is the most severe form of intestinal motility disorder, which leads to chronic or intermittent symptoms and signs of (sub-)ileus despite the absence of an intestinal obstruction. Small bowel motility disturbances may occur as primary diseases or secondary to a large number of other diseases and disturbances including rheumatological diseases and neurotoxic drugs. Pathological alterations affect the nervous system, smooth muscles, and/or mesenchymal structures such as the interstitial cells of Cajal or glia cells. Clinical symptoms are unspecific so that the initially suspected diagnosis is almost always wrong. Thus, extensive and stepwise diagnostic procedures are required involving specialized centers in order to exclude intestinal obstruction, to search for complications and potential causes of the disease, to quantify the extension and severity of the motility disorder, and to clarify the pathomechanism if possible. General therapeutic goals include maintenance of adequate nutritional status, improvement of propulsive motility, amelioration of abdominal symptoms, and avoidance and/or therapy of complications. Some CIPO patients require permanent parenteral nutrition. If this causes intolerable complications, small bowel transplantation can be considered in suitable patients as ultima ratio.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25854121     DOI: 10.1007/s00108-014-3606-7

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  25 in total

1.  Nutrition and quality of life following small intestinal transplantation.

Authors:  Stephen J D O'Keefe; Maureen Emerling; Darlene Koritsky; Dolly Martin; June Stamos; Hossam Kandil; Laura Matarese; Geoffrey Bond; Kareem Abu-Elmagd
Journal:  Am J Gastroenterol       Date:  2007-03-22       Impact factor: 10.864

2.  Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth.

Authors:  E C Lauritano; M Gabrielli; A Lupascu; A Santoliquido; G Nucera; E Scarpellini; F Vincenti; G Cammarota; R Flore; P Pola; G Gasbarrini; A Gasbarrini
Journal:  Aliment Pharmacol Ther       Date:  2005-07-01       Impact factor: 8.171

Review 3.  [Chronic intestinal pseudo-obstruction--review and update 2008].

Authors:  H Seidl; C Pehl; W Schepp; T Schmidt
Journal:  Z Gastroenterol       Date:  2008-07       Impact factor: 2.000

Review 4.  Intestinal transplantation.

Authors:  Thomas M Fishbein
Journal:  N Engl J Med       Date:  2009-09-03       Impact factor: 91.245

5.  [S3 guideline of the German Society for Digestive and Metabolic Diseases (DGVS) and the German Society for Neurogastroenterology and Motility (DGNM) to the definition, pathophysiology, diagnosis and treatment of intestinal motility].

Authors:  J Keller; T Wedel; H Seidl; M E Kreis; V Andresen; J C Preiss; P Layer; I van der Voort
Journal:  Z Gastroenterol       Date:  2011-03-09       Impact factor: 2.000

6.  Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth.

Authors:  M Di Stefano; S Malservisi; G Veneto; A Ferrieri; G R Corazza
Journal:  Aliment Pharmacol Ther       Date:  2000-05       Impact factor: 8.171

7.  Clinical characteristics of chronic idiopathic intestinal pseudo-obstruction in adults.

Authors:  S D Mann; H S Debinski; M A Kamm
Journal:  Gut       Date:  1997-11       Impact factor: 23.059

Review 8.  Human enteric neuropathies: morphology and molecular pathology.

Authors:  R De Giorgio; M Camilleri
Journal:  Neurogastroenterol Motil       Date:  2004-10       Impact factor: 3.598

9.  Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole.

Authors:  E C Lauritano; M Gabrielli; E Scarpellini; V Ojetti; D Roccarina; A Villita; E Fiore; R Flore; A Santoliquido; P Tondi; G Gasbarrini; G Ghirlanda; A Gasbarrini
Journal:  Eur Rev Med Pharmacol Sci       Date:  2009 Mar-Apr       Impact factor: 3.507

10.  Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction--a double-blind, placebo-controlled, cross-over, multiple n = 1 study.

Authors:  A V Emmanuel; M A Kamm; A J Roy; R Kerstens; L Vandeplassche
Journal:  Aliment Pharmacol Ther       Date:  2011-11-08       Impact factor: 8.171

View more
  1 in total

Review 1.  [Motility disorders of the colon].

Authors:  S Müller-Lissner
Journal:  Internist (Berl)       Date:  2015-06       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.